Equities

BGM Group Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BGM:NAQ

BGM Group Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.10
  • Today's Change-0.03 / -2.65%
  • Shares traded49.05k
  • 1 Year change-89.38%
  • Beta1.5758
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

BGM Group Ltd, formerly Qilian International Holding Group Ltd, is a company mainly engaged in the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives (TCMD) product, heparin product, sausage casings and fertilizers. The Company operates through three segments: Oxytetracycline & Licorice Products and TCMD segment, Fertilizer segment and Heparin Products and Sausage Casing segment. The Company's main brand is Qilian Shan. The Company principally operates its businesses within the domestic market.

  • Revenue in USD (TTM)26.85m
  • Net income in USD-2.72m
  • Incorporated1970
  • Employees323.00
  • Location
    BGM Group LtdNo. 152 Hongliang East 1St StreetNo. 1703, Tianfu New DistrictCHENGDU 610200ChinaCHN
  • Phone+86 2 864775180
  • Websitehttps://www.bgmgroupltd.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BGM:NAQ since
announced
Transaction
value
YX Management Co LtdDeal completed19 Mar 202519 Mar 2025Deal completed-89.26%486.43m
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Biostem Technologies Inc235.17m20.20m97.34m67.006.431.944.760.41390.90190.901911.602.982.822.614.65--24.25--55.07--97.33--8.59--4.09--0.0566--1,708.93--475.86------
Alpha Cognition Inc7.43m-19.47m106.10m52.00--2.34--14.29-1.37-1.370.50022.090.2894--5.22142,830.80-75.87-119.10-93.86-159.0573.09---262.18--6.03-7.910.00-------6.34------
Fortress Biotech Inc62.30m-5.34m112.05m101.00--2.00--1.80-0.293-0.2932.161.800.40391.504.35616,861.40-34.90-54.95-51.59-102.1371.5662.39-86.41-227.711.97-10.630.4503---31.769.5018.61--25.88--
Whitehawk Therapeutics Inc14.38m-15.62m134.32m22.0020.980.8546--9.340.13580.13580.28023.330.11380.56694.40359,600.00-12.36-52.97-13.76-60.6389.22---108.58-372.6716.76--0.00--6.69--3.15--47.49--
NDT Pharmaceuticals Inc-100.00bn-100.00bn152.00m1.00--0.8486----------1.12-----------164.47---452.47-------6,891.36----0.00---100.00--87.56------
Karyopharm Therapeutics Inc142.53m-124.62m157.11m279.00------1.10-14.58-14.5816.69-30.940.99771.344.48510,860.20-87.24-48.75-181.85-63.6495.9397.09-87.43-92.030.9842-2.55-----0.545128.8546.60---7.17--
Sanara Medtech Inc101.90m-6.24m168.97m141.00--27.47--1.66-0.7292-4.3411.860.68851.282.478.78722,724.30-8.03-15.12-10.00-18.6492.2588.92-6.29-14.701.600.30390.8801--33.3649.09-124.59---33.05--
BGM Group Ltd26.85m-2.72m178.70m323.00--0.5937--6.66-0.2816-0.28161.381.850.20873.218.6083,116.91-2.08-0.0792-2.36-0.106519.4110.38-9.95-0.09211.45-0.34080.00872,560.18-45.99-11.4581.46--16.40--
Tonix Pharmaceuticals Holding Corp10.30m-99.22m193.70m81.00--0.666--18.81-20.11-20.111.6922.730.05930.96652.75127,148.10-57.12-61.84-63.76-68.6734.31---963.38-2,797.359.62--0.00--29.94---11.47--47.82--
Coherus Oncology Inc83.57m-187.47m194.60m161.00--2.13--2.33-1.621.330.7210.75510.16361.760.9453366,526.30-36.70-21.44-106.02-31.5447.7971.26-224.34-42.661.23-15.120.3656--3.78-5.60111.98-20.51----
Journey Medical Corp59.40m-8.66m210.69m41.00--7.87--3.55-0.3645-0.36452.580.9820.7961.794.151,448,756.00-11.61-22.37-22.74-50.5564.4059.45-14.58-27.431.12-3.300.4928---29.119.96-280.79--44.27--
Mediwound Ltd20.93m-20.60m221.66m111.00--4.41--10.59-1.90-1.901.933.910.24754.593.69188,576.60-24.36-35.38-35.12-48.3918.5332.18-98.43-71.552.48--0.1416--8.22-8.65-350.03--51.27--
Opus Genetics Inc14.63m-68.20m251.03m18.00--39.37--17.16-1.76-1.760.29520.09250.3825--3.85812,944.40-178.28-76.30-330.00-86.90-----466.09-185.79----0.1518---42.30---476.13------
Data as of Feb 13 2026. Currency figures normalised to BGM Group Ltd's reporting currency: US Dollar USD

Institutional shareholders

0.16%Per cent of shares held by top holders
HolderShares% Held
Invesco Capital Management LLCas of 30 Sep 2025162.89k0.10%
SSgA Funds Management, Inc.as of 31 Dec 202549.14k0.03%
Geode Capital Management LLCas of 31 Dec 202547.16k0.03%
UBS Switzerland AG (Investment Management)as of 31 Dec 20252.43k0.00%
JPMorgan Securities LLC (Investment Management)as of 31 Dec 20251.75k0.00%
UBS Securities LLCas of 31 Dec 2025461.000.00%
Virtu Americas LLCas of 30 Sep 20250.000.00%
Mariner LLCas of 31 Dec 20250.000.00%
Millennium Management LLCas of 30 Sep 20250.000.00%
RBC Capital Markets LLC (Investment Management)as of 30 Sep 20250.000.00%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.